SCHEMBL6443675

SCHEMBL6443675

N#Cc1c(OCc2ccccn2)nc(N)nc1-c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 1/20 0.48
GRM5 P41594 1/20 0.43
ADORA1 P30542 6/20 0.40
ADORA2A P29274 5/20 0.40
TLR7 Q9NYK1 2/20 0.40
TLR8 Q9NR97 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALOX15 P16050 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FFAR1 O14842 2/20 0.38
SQOR Q9Y6N5 3/20 0.38
ALDH1A1 P00352 2/20 0.37
GLA P06280 2/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
HCRTR1 O43613 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441414 0.88 MGMT (0.55) MGMTADORA1ADORA2ATLR7TLR8
SCHEMBL6442328 0.88 SQOR (0.39) MGMTADORA1ADORA2AKDM4EALOX15
SCHEMBL6441608 0.88 ADORA2A (0.41) MGMTGRM5ADORA1ADORA2ATLR7
SCHEMBL5041645 0.88 ADORA1 (0.57) MGMTADORA1ADORA2ASQOR
SCHEMBL5044782 0.83 ADORA2A (0.56) MGMTADORA1ADORA2AKDM4EL3MBTL1
SCHEMBL5041663 0.83 ADORA2A (0.56) MGMTADORA1ADORA2AKDM4EALDH1A1
SCHEMBL6443053 0.83 ADORA2A (0.60) MGMTADORA1ADORA2AKDM4EL3MBTL1
SCHEMBL6443034 0.83 SQOR (0.41) ADORA1ADORA2AKDM4ESQOR
SCHEMBL6443037 0.82 SQOR (0.51) MGMTADORA1ADORA2ATLR7TLR8
SCHEMBL6441885 0.82 MGMT (0.53) MGMTADORA1ADORA2ATLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MGMT 3075/4885GRM5 509/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.